Company Description
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension.
In two Phase 2 pilot trials, RTN-001 achieved clinically meaningful placebo-adjusted reductions in systolic blood pressure and diastolic blood pressure in patients with hypertension and was generally well tolerated, with no drug-related serious adverse events reported.
We believe RTN-001 has the potential to be an effective treatment for hypertension with a favorable safety profile and thus be part of an anti-hypertensive treatment approach.
| Country | United States |
| Founded | 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Eric Keller |
Contact Details
Address: 1104 West Broad Street #1029 Falls Church, VA 22046 United States | |
| Phone | (703) 940-9761 |
| Website | retensionpharmaceuticals.com |
Stock Details
| Ticker Symbol | RTSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2002988 |
| Employer ID | 93-2592788 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric Keller, J.D. | Chief Executive Officer and Director |
| Alex Schwartz | Chief Financial Officer |
| Paul Sweetnam, Ph.D. | Chief Scientific Officer |
| Alison D. Schecter, M.D. | Chief Medical Officer |
| Sabine Bisson, Ph.D. | Chief Operating Officer |
| Michael Joseph Berendt, Ph.D. | Executive Chairman |
| Franklin M. Berger | Director |
| Donald Olds, M.B.A. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 14, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 16, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 1, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 17, 2026 | DRS | [Cover] Draft Registration Statement |
| May 6, 2025 | D | Notice of Exempt Offering of Securities |
| May 15, 2024 | D/A | Filing |
| Dec 5, 2023 | D | Notice of Exempt Offering of Securities |